StockGuru Spotlight June 22, 2011: Watch These Recent Mid-Teen Gainer Spotlights Poised to Break Out on News: PYMX $82M Market Cap and Up 19% Today; ASEN $298M Market Cap and Up 15% Today

StockGuru Spotlight June 22, 2011: Watch These Recent Mid-Teen Gainer Spotlights Poised to Break Out on News: PYMX $82M Market Cap and Up 19% Today; ASEN $298M Market Cap and Up 15% Today

StockGuru Spotlight

June 22, 2011

CSFFF, JCOF, MSLP, POTG

Dear Members:

These Spotlights have made tremendous moves. As you can see, StockGuru brings you the very stocks you want on your radar, in your portfolio and to trade.

StockGuru Spotlight Spotlight Price Symbol High Up As Much As Market Cap
May 26, 2011 $        0.655 PYMX $          0.78 19% $82.68M
March 23, 2011 $          1.40 FIGI.PK $          1.59 14% $22.02M
June 2, 2011 $        0.055 ASYI $        0.067 22% $11.21M
May 24, 2011 $          0.13 UFFC $          0.16 23% $6.09M
May 17, 2011 $          6.98 ASEN $          8.00 15% $298.61M
June 1, 2011 $          2.65 DYSC $          3.00 13% $50.47M

PolyMedix (OTCBB: PYMX) is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug candidates. PolyMedix’s lead antibiotic compound, PMX-30063, is currently in a Phase 2 clinical trial for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staph, including MRSA. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedix’s lead heptagonist compound, PMX-60056, is in a Phase 2 clinical trial in patients undergoing PCI procedures. PMX-60056 is designed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH.

In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides(R). PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces.

StockGuru brings you trading news you can use and meaningful trends:

Our StockGuru Spotlight Picks Are Published Before the Open Each Morning

StockGuru Spotlights are featured on our web site. We have an RSS feed and an exclusive twitter feed for StockGuru Spotlights. We also issue press releases on the StockGuru Spotlights; you can see proof positive our notice to you is truly an advanced notice. StockGuru is not not jumping on these after they move. Here is the link to BOOKMARK for Spotlights: http://www.stockguru.com/tag/spotlight

Don’t Miss Our on Spotlight Stocks! It is critical to catch these alerts in the morning prior to the market open. I have been asked several times recently how to get them.

IMPORTANT: Bookmark this link: http://www.stockguru.com/tag/spotlight Check This Link Every Morning for New Spotlight Stocks All of these are date and time stamped so you know what is current today. You can also just go to STOCKGURU.COM and look for the link in the top navigation for “StockGuru Spotlight.” You can also put the RSS link into your RSS reader, such as my favorite “Google Reader.”

There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.

StockGuru is in its Ninth Year!

Left Menu Icon
Right Menu Icon